BioSpace News Archive

May 6, 2020 12:30 UTC Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the pu

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the availability of its 2019 Trinity Drug Index, a commercial analysis of 26 unique therapeutic agents approved in 2016.

DILIsym Services, Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, announced that the U.S. Food and Drug Administration has again renewed its multi-seat license for the company’s leading quantitative systems toxicology modeling software, DILIsym®.

SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA).

Allovate Therapeutics , a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of all ages. Allovate’s lead product, Allerdent ® , is

Otezla Treatment Resulted in Significant Improvements in Measures of Mild-to-Moderate Psoriasis Compared With Placebo Data Will be Submitted to the U.S. Food and Drug Administration (FDA) for Inclusion in Otezla Prescribing Information

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled “Composition and Method for Treating Colon Cancer with

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2020 and highlighted recent corporate updates.

AliveCor , the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, announced a strategic collaboration with the Clifford Lab at Emory University School of Medicine , and the Geor

Results published in CHEST Journal demonstrate benefits of using dynamic measures to guide fluid therapy decisions